Illumina (BSP:I1LM34) ROCE % : -4.29% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Illumina ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Illumina's annualized ROCE % for the quarter that ended in Mar. 2024 was -4.29%.

Illumina ROCE % Historical Data

The historical data trend for Illumina's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina ROCE % Chart

Illumina Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

20.30

15.54

9.50

-34.89

-11.13

Illumina Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-2.43	-2.84	-34.01	-6.91	-4.29

Illumina ROCE % Calculation

Illumina's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-5095.792	/	( ( (64266.641 - 14545.494)	+	(49541.878 - 7692.686) )	/ 2 )
	=	-5095.792	/	( (49721.147	+	41849.192)	/ 2 )
	=	-5095.792	/	45785.1695
	=	-11.13 %

Illumina's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-1812.648	/	( ( (49541.878 - 7692.686)	+	(49997.192 - 7340.225) )	/ 2 )
	=	-1812.648	/	( ( 41849.192	+	42656.967 )	/ 2 )
	=	-1812.648	/	42253.0795
	=	-4.29 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Illumina (BSP:I1LM34) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Illumina ROCE % Related Terms

Thank you for viewing the detailed overview of Illumina's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Illumina (BSP:I1LM34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (BSP:I1LM34) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ILMN:USA ILMN:Mexico 1ILMN:Italy ILU:Germany ILU:Germany ILU:Germany ILMN:Austria

Address

5200 Illumina Way, San Diego, CA, USA, 92122

Website

https://www.illumina.com

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina (BSP:I1LM34) Headlines

No Headlines